Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Duloxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 13/20 | 0.98 |
| ▸ | SLC6A4 known ✓ | P31645 | 13/20 | 0.98 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.98 |
| ▸ | MLNR | O43193 | 1/20 | 0.98 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.98 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.98 |
| ▸ | HTR1A | P08908 | 1/20 | 0.98 |
| ▸ | GAA | P10253 | 1/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.98 |
| ▸ | DRD2 | P14416 | 1/20 | 0.98 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.98 |
| ▸ | HTR2A | P28223 | 1/20 | 0.98 |
| ▸ | HTR2C | P28335 | 1/20 | 0.98 |
| ▸ | MC4R | P32245 | 1/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Duloxetine SCHEMBL120750 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL119403 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL29389952 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| (R)-Duloxetine SCHEMBL3901869 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL2384759 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| (R)-Duloxetine SCHEMBL30523711 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL28196267 | 0.99 | SLC6A2 (0.95) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL3803 | 0.99 | SLC6A4 (1.00) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL10036575 | 0.99 | SLC6A4 (1.00) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL8291 | 0.99 | SLC6A4 (1.00) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957227-B2 | Preparation of Duloxetine® hydrochloride using optically active methylhydroxylaminopropanol compound as an intermediate | SCI PHARMTECH, INC. (TW) | 2015-02-17 | — | — | US | claimed |
| CN-104163811-A | New method for preparation of duloxetine hydrochloride | CHONGQING SHENGHUAXI PHARMA CO | 2014-11-26 | — | — | CN | claimed |
| US-20140005414-A1 | PREPARATION OF DULOXETINE HYDROCHLORIDE USING OPTICALLY ACTIVE METHYLHYDROXYLAMINOPROPANOL COMPOUND AS AN INTERMEDIATE | SCI PHARMTECH, INC. (TW) | 2014-01-02 | — | — | US | claimed |
| CN-102579403-B | Duloxetine hydrochloride drug composition | TIANJIN SONGRUI MEDICAL TECH | 2013-08-21 | — | — | CN | claimed |
| CN-102908331-A | Duloxetine hydrochloride enteric capsules and preparation method thereof | ZHEJIANG JIUZHOU PHARMACEUTICAL TECHNOLOGY CO LTD | 2013-02-06 | — | — | CN | claimed |
| CN-102579403-A | Duloxetine hydrochloride drug composition | TIANJIN SONGRUI MEDICAL TECH | 2012-07-18 | — | — | CN | claimed |
| WO-2011077443-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF DULOXETINE HYDROCHLORIDE | BIOCON LIMITED (IN) | 2011-06-30 | — | — | WO | claimed |
| US-20100069649-A1 | METHOD OF PURIFICATION OF (S)-N-METHYL-3-(1-NAPHTYLOXY)-3-(2-THIENYL) PROPYLAMINE HYDROCHLORIDE (DULOXETINE) | ZENTIVA K.S. (CZ) | 2010-03-18 | — | — | US | claimed |
| CN-101631783-A | Crystalline duloxetine hydrochloride | ARROW INT LTD | 2010-01-20 | — | — | CN | claimed |
| EP-1113797-B1 | USE OF DULOXETINE FOR THE TREATMENT OF FIBROMYALGIA | LILLY CO ELI (US) | 2009-11-25 | — | — | EP | claimed |
| US-7550605-B2 | Process for preparation of an anitdepressant compound | SUN PHARMACEUTICAL INDUSTRIES LTD. (IN) | 2009-06-23 | — | — | US | claimed |
| CN-100486974-C | Method of preparing dulouxetine | UNIV TIANJIN (CN) | 2009-05-13 | — | — | CN | claimed |
| US-20070191616-A1 | Process for preparation of an antidepressant compound | SUN PHAMACEUUTICAL INDUSTRIES LTD. (IN) | 2007-08-16 | — | — | US | claimed |
| CN-101012219-A | Method of preparing dulouxetine | UNIV TIANJIN (CN) | 2007-08-08 | — | — | CN | claimed |
| EP-1113797-A4 | TREATMENT OF PERSISTENT PAIN | LILLY CO ELI (US) | 2006-07-05 | — | — | EP | claimed |
| CN-1149991-C | Treatment of persistent pain | — | 2004-05-19 | — | — | CN | claimed |
| US-6596756-B1 | A method of using N-methyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine to treat persistent pain. analgesics | ELI LILLY AND COMPANY | 2003-07-22 | — | — | US | claimed |
| CN-1316904-A | Treatment of persistent pain | LILLY CO ELI (US) | 2001-10-10 | — | — | CN | claimed |
| EP-1113797-A1 | TREATMENT OF PERSISTENT PAIN | ELI LILLY AND COMPANY (US) | 2001-07-11 | — | — | EP | claimed |
| WO-2000015223-A1 | TREATMENT OF PERSISTENT PAIN | ELI LILLY AND COMPANY (US) | 2000-03-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005414-A1 | PREPARATION OF DULOXETINE HYDROCHLORIDE USING OPTICALLY ACTIVE METHYLHYDROXYLAMINOPROPANOL COMPOUND AS AN INTERMEDIATE | ADRA1A, ADRA2A, ADRB1 | SLC6A2 120/4885SLC6A4 96/4885SLC6A3 168/4885 |
| US-20100069649-A1 | METHOD OF PURIFICATION OF (S)-N-METHYL-3-(1-NAPHTYLOXY)-3-(2-THIENYL) PROPYLAMINE HYDROCHLORIDE (DULOXETINE) | PNMT, SLC6A2, HTR7 | SLC6A2 2/4885SLC6A4 4/4885SLC6A3 7/4885 |
| US-20070191616-A1 | Process for preparation of an antidepressant compound | TPH1, TPH2, HTR4 | SLC6A2 13/4885SLC6A4 5/4885SLC6A3 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.